Indian hospitals face limited impact from cancer drug price cap, Goldman Sachs says

Goldman Sachs group

09/10/2026 05:18

** Goldman Sachs notes limited impact for hospitals from India's 30% margin cap on prices of non-scheduled cancer medicines
** Says initial discussions with hospital chains suggest such drugs make up less than 5% of hospital revenues, 2%-2.5% of operating profit
** Adds, hospitals can recoup losses via marginal repricing of services like drug administration charges
** An expert committee will finalise list of medicines to be covered, government notification says
** Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS and Fortis Healthcare FOHE.NS shares rise between 1.6% and 2.5% following 11%-11.5% drop since September 30 on anticipation of cap
** YTD, FOHE and MAXE down 11.7% and 14.8%, respectively, while APLH up 11%

(Reporting by Vivek Kumar M)
((VivekKumar.M@thomsonreuters.com;))